KR101350741B1 - 이미다졸 유도체 및 그의 도파민-베타-하이드록실라제의 말초 신경 선택적 억제제로서의 용도 - Google Patents

이미다졸 유도체 및 그의 도파민-베타-하이드록실라제의 말초 신경 선택적 억제제로서의 용도 Download PDF

Info

Publication number
KR101350741B1
KR101350741B1 KR1020127005102A KR20127005102A KR101350741B1 KR 101350741 B1 KR101350741 B1 KR 101350741B1 KR 1020127005102 A KR1020127005102 A KR 1020127005102A KR 20127005102 A KR20127005102 A KR 20127005102A KR 101350741 B1 KR101350741 B1 KR 101350741B1
Authority
KR
South Korea
Prior art keywords
compound
mmol
ethyl acetate
dihydroimidazole
mixture
Prior art date
Application number
KR1020127005102A
Other languages
English (en)
Korean (ko)
Other versions
KR20120038014A (ko
Inventor
데이비드 알렉산더 레아르몬스
다 실바 파트리키오 마누엘 비에라 아라우조 소아레스
알렉산더 벨리아에브
Original Assignee
바이알 - 포르텔라 앤드 씨에이 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이알 - 포르텔라 앤드 씨에이 에스에이 filed Critical 바이알 - 포르텔라 앤드 씨에이 에스에이
Priority claimed from PCT/GB2003/004430 external-priority patent/WO2004033447A1/en
Publication of KR20120038014A publication Critical patent/KR20120038014A/ko
Application granted granted Critical
Publication of KR101350741B1 publication Critical patent/KR101350741B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127005102A 2002-10-11 2003-10-10 이미다졸 유도체 및 그의 도파민-베타-하이드록실라제의 말초 신경 선택적 억제제로서의 용도 KR101350741B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0223719A GB2393958A (en) 2002-10-11 2002-10-11 Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0223719.6 2002-10-11
GB0224306A GB2394223B (en) 2002-10-11 2002-10-18 Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation
GB0224306.1 2002-10-18
PCT/GB2003/004430 WO2004033447A1 (en) 2002-10-11 2003-10-10 Imidazole derivatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020057006221A Division KR101155159B1 (ko) 2002-10-11 2003-10-10 이미다졸 유도체 및 그의 도파민-베타-하이드록실라제의말초 신경 선택적 억제제로서의 용도

Publications (2)

Publication Number Publication Date
KR20120038014A KR20120038014A (ko) 2012-04-20
KR101350741B1 true KR101350741B1 (ko) 2014-01-10

Family

ID=9945777

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127005102A KR101350741B1 (ko) 2002-10-11 2003-10-10 이미다졸 유도체 및 그의 도파민-베타-하이드록실라제의 말초 신경 선택적 억제제로서의 용도

Country Status (11)

Country Link
KR (1) KR101350741B1 (de)
CN (1) CN100393715C (de)
AR (2) AR041589A1 (de)
AT (5) ATE500248T1 (de)
CY (2) CY1108452T1 (de)
DE (4) DE60336772D1 (de)
DK (2) DK1408038T3 (de)
ES (5) ES2384118T3 (de)
GB (2) GB2393958A (de)
HK (1) HK1116188A1 (de)
SI (2) SI1408038T1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
CN103380128B (zh) * 2010-12-22 2017-03-01 拜欧波尔特拉及正大有限公司 晶型及其制备方法
GB201316410D0 (en) * 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0335375A2 (de) 1988-03-30 1989-10-04 Warner-Lambert Company Antihyperlipidemische und antiatherosclerotische Verbindungen und Zusammensetzungen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL82401A0 (en) * 1986-05-06 1987-11-30 Merrell Dow Pharma Dopamine beta hydroxy-lase inhibiting imidazole derivatives and pharmaceutical compositions containing them
EP0757677B1 (de) * 1994-04-26 2003-06-18 Syntex (U.S.A.) LLC Benzocyclohexylimidazolthion-derivate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0335375A2 (de) 1988-03-30 1989-10-04 Warner-Lambert Company Antihyperlipidemische und antiatherosclerotische Verbindungen und Zusammensetzungen

Also Published As

Publication number Publication date
AR095674A2 (es) 2015-11-04
DE60336275D1 (de) 2011-04-14
ES2364919T3 (es) 2011-09-16
ATE500248T1 (de) 2011-03-15
ATE550335T1 (de) 2012-04-15
SI1908760T1 (sl) 2011-05-31
CY1112457T1 (el) 2015-12-09
GB0223719D0 (en) 2002-11-20
ES2384118T3 (es) 2012-06-29
CY1108452T1 (el) 2014-04-09
DK1408038T3 (da) 2008-11-24
GB2394223A (en) 2004-04-21
GB2393958A (en) 2004-04-14
DK1908760T3 (da) 2011-07-25
GB2394223B (en) 2007-05-16
DE60336772D1 (de) 2011-05-26
ATE500247T1 (de) 2011-03-15
DE60336276D1 (de) 2011-04-14
ATE505465T1 (de) 2011-04-15
CN100393715C (zh) 2008-06-11
ES2309279T3 (es) 2008-12-16
KR20120038014A (ko) 2012-04-20
ES2361938T3 (es) 2011-06-24
ATE403652T1 (de) 2008-08-15
ES2361939T3 (es) 2011-06-24
AR041589A1 (es) 2005-05-26
SI1408038T1 (sl) 2008-10-31
CN1726211A (zh) 2006-01-25
HK1116188A1 (en) 2008-12-19
GB0224306D0 (en) 2002-11-27
DE60322642D1 (de) 2008-09-18

Similar Documents

Publication Publication Date Title
KR101155159B1 (ko) 이미다졸 유도체 및 그의 도파민-베타-하이드록실라제의말초 신경 선택적 억제제로서의 용도
KR101598482B1 (ko) 도파민-베타-히드록실라아제의 저해제인 1,3-디히드로이미다졸-2-티온 유도체
HU198479B (en) Process for producing 1-substituted imidazole derivatives and pharmaceutical compositions comprising same as active ingredient
KR101350741B1 (ko) 이미다졸 유도체 및 그의 도파민-베타-하이드록실라제의 말초 신경 선택적 억제제로서의 용도
CZ4296A3 (en) Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclyl)methylamine derivatives
EP0463944A1 (de) Acylbenzoxazolinone, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten
HU205087B (en) Process for producing 2,2'-bi(1h-imidazole) derivatives
CA2674305A1 (en) Therapy
WO2002053157A1 (en) Thiazolidine derivative
WO2016205031A1 (en) Fluoropyridyl pyrazol compounds

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20161220

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20171221

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20181220

Year of fee payment: 6